PickASO Project
Therapy to activate autophagy (via ASO)
Pre-clinical/DevelopmentActive
Key Facts
Indication
Therapy to activate autophagy (via ASO)
Phase
Pre-clinical/Development
Status
Active
Company
About DIVERCHIM CDMO
DIVERCHIM CDMO is a specialized French contract development and manufacturing organization focused on high-value, low-volume small molecule active ingredients. It leverages over 20 years of collective expertise to serve niche markets such as orphan drugs, radiopharmaceuticals, and novel therapeutic modalities like antisense oligonucleotides (ASOs). With a GMP and FDA-registered site, the company offers integrated services from route scouting to commercial manufacturing, positioning itself as a key partner for emerging biotechs and larger players in targeted therapies.
View full company profile